

#247

COMPLETE

Collector: Web Link 1 (Web Link)
Started: Tuesday, September 08, 2026 11:43:42 AM
Last Modified: Tuesday, September 08, 2026 12:12:09 PM
Time Spent: 00:28:27
IP Address: 192.186.82.6

Page 2: Part 1

Q1

Title of activity

Speaker at Medical CSACI Dermatology NAB

Q2

Date of activity

October 15th - 17th, 2026

Q3

Speaker

What is your role in the CPD activity? (Select all that apply)

Q4

Community Practice

What's your practice type?

Q5

Please indicate:

I HAVE a relationship with a for-profit and/or a not-for-profit organization to disclose.If so, please indicate below (questions 5 to 10) the organization(s) with which you have/had a relationship over the previous two years and briefly describe the nature of that relationship.

Q6

Any direct financial payments including receipt of honoraria

Name of FOR PROFIT and/or NOT-for-profit organization(s)
(separate with commas)

AbbVie, Acelyrin Inc., Alumis Inc., AMGEN Inc., AnaptysBio, Apogee Therapeutics, Apollo Therapeutics, Arcutis Pharmaceuticals Inc., Aristea Therapeutics, Attovia Therapeutics Inc., Bausch Health, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Dermira Inc., Eli Lilly and Company, Galderma SA, GlaxoSmithKline, Incyte Biosciences, Insmmed Inc., Jamp Pharma, Janssen Inc., LEO Pharma, L'Oreal, Meiji Seika, Merck, MoonLake Immunotherapeutics, Nectar Therapeutics, Novartis Pharmaceuticals, Organon Canada Inc., Oruka Therapeutics, Pfizer Inc., Q32 Bio Inc., Regeneron Pharmaceuticals Inc., Reistone Biopharma, Sanofi Genzyme, Sun Pharmaceuticals, Takeda, Tarsus, UCB, Union Therapeutics, Ventyx, and Vyne Therapeutics.

Description of relationship(s)

Dr. Gooderham has acted as Advisory Board participant, Principal Investigator, Speaker or Consultant

Q7

Membership on advisory boards or speakers' bureaus

Name of FOR PROFIT and/or NOT-for-profit organization(s)
(separate with commas)

AbbVie, AMGEN Inc., Apogee Therapeutics, Arcutis Pharmaceuticals Inc., Bausch Health, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Galderma SA, Janssen Inc., LEO Pharma, L'Oreal, Novartis Pharmaceuticals, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi Genzyme, Sun Pharmaceuticals, Takeda, UCB, and Union Therapeutics.

Description of relationship(s)

Advisory Board participant or Speaker Bureau

Q8

Funded grants or clinical trials

Name of FOR PROFIT and/or NOT-for-profit organization(s)
(separate with commas)

AbbVie, Acelyrin Inc., Alumis Inc., AMGEN Inc., AnaptysBio, Apogee Therapeutics, Arcutis Pharmaceuticals Inc., Aristea Therapeutics, Attovia Therapeutics Inc., Bausch Health, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Dermira Inc., Eli Lilly and Company, Galderma SA, GlaxoSmithKline, Incyte Biosciences, Insmmed Inc., Jamp Pharma, Janssen Inc., LEO Pharma, Meiji Seika, Merck, MoonLake Immunotherapeutics, Nectar Therapeutics, Novartis Pharmaceuticals, Organon Canada Inc., Oruka Therapeutics, Pfizer Inc., Q32 Bio Inc., Regeneron Pharmaceuticals Inc., Reistone Biopharma, Sanofi Genzyme, Sun Pharmaceuticals, Takeda, Tarsus, UCB, Ventyx, and Vyne Therapeutics.

Description of relationship(s)

Principal Investigator

Q9

Patents on a drug, product or device

Name of FOR PROFIT and/or NOT-FOR PROFIT organization(s)
(separate with commas)

n/a

Q10

Respondent skipped this question

All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity

Page 3: Part 2: To be completed by presenters only

Q11

No

I intend to use trade names during my presentation. Note: Only generic names should be used whenever possible. If trade names are used, they should be accompanied by the generic name.

Q12

No

I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. "off-label" use of medication). Note: You must declare all off-label use to the audience during your presentation.

Q13**N/A**

If you answered "Yes" to the previous question, are the medications recommended manufactured by companies you have received funding from?

Q14**Yes**

I acknowledge that the National Standard requires that any description of therapeutic options utilize generic names (or both generic and trade names) and not reflect exclusivity and branding.

Page 4: Part 3 (Anonymous & Optional): Equity, Diversity and Inclusion (EDI)

Q15**Yes**

I confirm that I've completed the EDI Survey linked above

Page 5: PART 4: Acknowledgement and signature (for all)

Q16

First Name:

Melinda

Q17

Last Name:

Gooderham

Q18**She/Her**

Gender Pronouns - How would you like us to address you?

Q19

Please review and check the items below.

I confirm that the above information is accurate and complete.

,

I understand that this information may be publicly available
